MA31663B1 - Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe - Google Patents

Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe

Info

Publication number
MA31663B1
MA31663B1 MA32377A MA32377A MA31663B1 MA 31663 B1 MA31663 B1 MA 31663B1 MA 32377 A MA32377 A MA 32377A MA 32377 A MA32377 A MA 32377A MA 31663 B1 MA31663 B1 MA 31663B1
Authority
MA
Morocco
Prior art keywords
reversible
intervasive
inhibitor
oral
dosage
Prior art date
Application number
MA32377A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Daniel D Gretler
Pamela B Conley
Patrick Andre
Athiwat Hutchaleelaha
David R Phillips
Anjali Pandey
Huang Wolin
Robert M Scarborough
Original Assignee
Portoal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portoal Pharmaceuticals Inc filed Critical Portoal Pharmaceuticals Inc
Publication of MA31663B1 publication Critical patent/MA31663B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA32377A 2007-05-02 2009-11-26 Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe MA31663B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
MA31663B1 true MA31663B1 (fr) 2010-09-01

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32377A MA31663B1 (fr) 2007-05-02 2009-11-26 Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe

Country Status (17)

Country Link
US (2) US20090048216A1 (pt-PT)
EP (1) EP2079464A2 (pt-PT)
JP (1) JP2010526101A (pt-PT)
KR (1) KR20100029746A (pt-PT)
CN (1) CN101795682A (pt-PT)
AU (1) AU2008247483A1 (pt-PT)
BR (1) BRPI0811476A2 (pt-PT)
CA (1) CA2686203A1 (pt-PT)
CO (1) CO6241104A2 (pt-PT)
EA (1) EA200901473A1 (pt-PT)
EC (1) ECSP099778A (pt-PT)
GT (1) GT200900284A (pt-PT)
IL (1) IL201834A0 (pt-PT)
MA (1) MA31663B1 (pt-PT)
MX (1) MX2009011843A (pt-PT)
TN (1) TN2009000451A1 (pt-PT)
WO (1) WO2008137753A2 (pt-PT)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2428514A1 (en) * 2005-11-03 2012-03-14 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
EP2132186A1 (en) * 2007-03-06 2009-12-16 Novartis AG Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
CN101720324A (zh) * 2007-05-02 2010-06-02 波托拉医药品公司 [4-(6-氟-7-甲基氨基-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基-磺酰基脲盐、其相关的形式和方法
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9925265B2 (en) 2009-11-11 2018-03-27 Chiesi Farmaceutici S.P.A. Methods of treating or preventing stent thrombosis
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
KR20110115578A (ko) * 2008-12-30 2011-10-21 트롬보로직 에이피에스 장기 부전이 발달할 증가된 위험이 있는 중증 질환 환자의 확인 방법 및 이의 치료를 위한 화합물
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
ES2550033T3 (es) * 2009-12-23 2015-11-04 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor
EP2523657A1 (en) 2010-01-12 2012-11-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
US9029095B2 (en) 2010-12-01 2015-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method and kits for determining platelet susceptibility to activation in a patient
CN103339126B (zh) * 2010-12-03 2016-06-29 博尔托拉制药公司 式(i)化合物的固态形式及其药物组合物、剂型和使用方法
TWI765002B (zh) 2017-03-15 2022-05-21 瑞士商愛杜西亞製藥有限公司 受體拮抗劑之皮下投藥
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
EP2428514A1 (en) 2005-11-03 2012-03-14 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Also Published As

Publication number Publication date
CA2686203A1 (en) 2008-11-13
CO6241104A2 (es) 2011-01-20
WO2008137753A2 (en) 2008-11-13
TN2009000451A1 (en) 2011-03-31
JP2010526101A (ja) 2010-07-29
EP2079464A2 (en) 2009-07-22
US20120009172A1 (en) 2012-01-12
CN101795682A (zh) 2010-08-04
GT200900284A (es) 2012-01-31
MX2009011843A (es) 2010-04-22
IL201834A0 (en) 2010-06-16
WO2008137753A3 (en) 2009-02-12
KR20100029746A (ko) 2010-03-17
ECSP099778A (es) 2010-01-29
EA200901473A1 (ru) 2010-06-30
BRPI0811476A2 (pt) 2014-11-04
AU2008247483A1 (en) 2008-11-13
US20090048216A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
BRPI0407922A (pt) derivados de isoquinolina e métodos de uso destes
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA32049B1 (fr) Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp
SG146657A1 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
NZ594589A (en) 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
UA101601C2 (uk) Інгібітори амідогідролази жирних кислот
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
DK1819227T3 (da) Farmaceutisk formulering af decitabin
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA29856B1 (fr) Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
WO2007046868A3 (en) Thiazolidine derivatives and their uses as therapeutic agents
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
BR0308290A (pt) Tratamento e prevenção de distúrbios inflamatórios
MA33571B1 (fr) Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
MY151295A (en) Pyrimidyl indoline compound
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы